Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Dexmedetomidine vs magnesium with lidocaine for eye block during DCR surgery

Official title: Hemodynamic Effect of Dexmedetomidine Versus Magnesium Sulphate as an Adjuvant to Lidocaine in Preemptive Peribulbar Block in Patients Undergoing Dacryocystorhinostomy Under General Anesthesia: A Randomized Controlled Trial

Run by Cairo University · NCT07675616 · Data updated 2026-11-12

This trial tests whether adding dexmedetomidine or magnesium sulfate to lidocaine for a preemptive peribulbar block can better manage blood pressure and heart rate in adults undergoing DCR surgery under general anesthesia.

More Dexmedetomidine trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment60 (estimated)
SponsorCairo University
Academic / other
Locations1 site (Cairo)
StatusRecruiting
StartedMay 16, 2026
Main results expectedDecember 1, 2026
Study endsDecember 1, 2026
Registry record updatedJune 30, 2026
Trial IDNCT07675616 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18 years or older, ASA I–II, undergoing elective DCR under general anesthesia, without coagulopathy or infection at the injection site and without uncontrolled systemic disease.

Probably not a fit

Patients with no measurable hemodynamic differences or who do not respond to the chosen adjuvant may not experience a benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study compares two adjuvants—dexmedetomidine and magnesium sulfate—mixed with lidocaine for a preemptive peribulbar block in adults undergoing elective dacryocystorhinostomy under general anesthesia. The goal is to observe how these adjuvants influence intraoperative hemodynamics. Participants are adults (ASA I–II) undergoing DCR, with exclusions including coagulopathy, infections at the injection site, uncontrolled systemic disease, and uncooperative behavior. The trial assesses whether one adjuvant provides more stable hemodynamics or better analgesia compared to the other or lidocaine alone. Lead institution is Cairo University.

Why it matters

Potential benefit: If successful, the adjuvant with better hemodynamic stability could improve intraoperative safety and comfort for patients undergoing DCR under general anesthesia.

How similar studies have gone: Previous work has explored dexmedetomidine and magnesium as adjuvants in regional anesthesia with varying success; this study adds a direct comparison in ophthalmic surgery.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age ≥ 18 years.
* Both sexes.
* American Society of Anesthesiologists (ASA) physical status I or II.
* Undergoing elective Dacryocystorhinostomy (DCR) surgery under general anesthesia.

Exclusion Criteria:

* Patients have local infection.
* Allergic reaction or complications of the local anaesthesia (LA).
* Coagulopathy defined as international normalized ratio (INR) \> 1.5, platelet count \< 100,000/mm³, or ongoing anticoagulant therapy not adequately discontinued.
* Uncontrolled systemic disease, defined as poorly controlled hypertension \[systolic blood pressure (SBP) \> 160 mmHg\], uncontrolled diabetes mellitus (HbA1c \> 8.5%), unstable ischemic heart disease, or decompensated hepatic or renal disease.
* Uncooperative patients.

Where it's running

  • Cairo University
    Cairo, Egypt
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.